Atossa Therapeutics Reports Q4 and FY2025 Results, Highlights (Z)-Endoxifen Progress in DMD

ATOSSA THERAPEUTICS, INC.

Atossa reported FY2025 operating expenses of $37.1M, up from $27.6M; R&D expenses increased 50% to $21.2M.
Received FDA Rare Pediatric Disease and Orphan Drug designations for (Z)-endoxifen in Duchenne Muscular Dystrophy.
Added Kathy Puyana Theall, M.D. and Adebola Giwa, M.D. as Medical Directors for breast oncology and rare diseases.
Interest income decreased to $2.4M from $4.1M; no impairment charge in 2025 vs $1.7M in 2024.
(Z)-endoxifen being evaluated in multiple settings including breast cancer and rare diseases DMD and MAS.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.